The efficacy and drug survival of the biosimilar infliximab (CT-P13) compared to the original reference infliximab in inflammatory rheumatic diseases results from the turkbio registry


USLU S., CAN G., ŞENEL S., DALKILIÇ H. E. , İNANÇ G. N. , AKAR S., ...More

EULAR2018, 13 - 16 June 2018

  • Publication Type: Conference Paper / Summary Text